Health Condition 1: A920- Chikungunya virus disease Health Condition 2: A90- Dengue fever [classical dengue]
Conditions
Interventions
None listed
Sponsors
Dr Winsley Rose
Eligibility
Inclusion criteria
Inclusion criteria: 1 Individuals currently residing and likely to stay till the end of one year in the study area 2 Consented to participate in both sections of the study (Sero Prevalence and AFI Surveillance) and follow all procedures.
Exclusion criteria
Exclusion criteria: Ongoing fever episodes or history of AFI on or before enrolment for the cohort
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 Age specific attack rate 2 Age-specific cumulative incidence of asymptomatic infections 3 Age-specific cumulative incidence of symptomatic events 4. Age Specific sero prevalence and seroincidence of neutralizing antibodies 5. Symptomatic proportion of cases (asymptomatic fraction) 6. Prevalence and incidence of Circulating serotypes 7. Population groups most at risk 8. Validity of IgG ELISA 9. Economic burden of Dengue and Chikungunya Timepoint: The AFI study will be conducted for a period of 12 months with serosurvey for dengue and chikungunya at baseline and endline | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactWinsley Rose
Christian Medical College, Vellore
Outcome results
None listed